References

1. FDA. (2014). Preventable Adverse Drug Reactions: A Focus on Drug Interactions.  

2. Epstein, R. S., Moyer, T. P., Aubert, R. E., O’Kane, D. J., Xia, F., Verbrugge, R. R., . . . Teagarden, J. R. (2010). Warfarin Genotyping Reduces Hospitalization Rates. Journal of the American College of Cardiology, 55(25), 2804-2812. doi:10.1016/j.jacc.2010.03.009

3. FDA. (2010). Costs Associated with ADRs.

4.  FDA. (2015). Table of Pharmacogenomic Biomarkers in Drug Labeling. 

5. Evans, W. E. (1999). Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science, 286(5439), 487-491. doi:10.1126/science.286.5439.487

6. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138(1), 103-141. doi:10.1016/j.pharmthera.2012.12.007

7. Mega, J. L., Simon, T., Collet, J., Anderson, J. L., Antman, E. M., Bliden, K., . . . Sabatine, M. S. (2010). Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. Jama, 304(16), 1821. doi:10.1001/jama.2010.1543

8. Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . EU-PACT Group. (2013, December 12). A Randomized Trial of Genotype-Guided Dosing of Warfarin. NEJM, 369(24), 2294-303. doi: 10.1056/NEJMoa1311386

9. Ansell, J., Hirsh, J., Jacobson, A., Crowther, M., Palareti, G., & American College of Chest Physicians. (2008). Pharmacology and Management of the Vitamin K Antagonists *. Chest CHEST Journal, 133(6_suppl). doi:10.1378/chest.08-0670

10. Driest, S. V., Shi, Y., Bowton, E., Schildcrout, J., Peterson, J., Pulley, J., . . . Roden, D. (2013). Clinically Actionable Genotypes Among 10,000 Patients With Preemptive Pharmacogenomic Testing. Clin Pharmacol Ther Clinical Pharmacology & Therapeutics, 95(4), 423-431. doi:10.1038/clpt.2013.229

11.  Johnson, J. A., Gong, L., Whirl-Carrillo, M., Gage, B. F., Scott, S. A., Stein, C. M., . . . Altman, R. B. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clin Pharmacol Ther Clinical Pharmacology & Therapeutics, 90(4), 625-629. doi:10.1038/clpt.2011.185

12. Chong, K. (2011, November 11). Clopidogrel Dosing and CYP2C19. 

13. TCT 2013: Transcatheter Cardiovascular Therapeutics 25th Annual Scientific Symposium

14. Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009). The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects. Journal of the American College of Cardiology, 54(17), 1609-1616. doi:10.1016/j.jacc.2009.04.053

15. Lilja, J. J., Neuvonen, M., & Neuvonen, P. J. (2004). Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. British Journal of Clinical Pharmacology Br J Clin Pharmacol, 58(1), 56-60. doi:10.1111/j.1365-2125.2004.02095.x

16. Pasanen, M. K., Neuvonen, M., Neuvonen, P. J., & Niemi, M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics, 16(12), 873-879. doi:10.1097/01.fpc.0000230416.82349.90

17. Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., Mcleod, H. L., Voora, D., . . . Niemi, M. (2012). The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy. Clin Pharmacol Ther Clinical Pharmacology & Therapeutics, 92(1), 112-117. doi:10.1038/clpt.2012.57